Skip to main content
. 2021 Jun 2;11(6):e048808. doi: 10.1136/bmjopen-2021-048808

Table 2.

Baseline characteristics

Whole group (n=22) Intervention (n=11) Control (n=11)
Gender: male (%) 16 (73) 7 (64) 8 (73)
Age (years) 76 (74, 82) 77 (73, 81) 76 (74, 84)
MRC dyspnoea score 4 (4, 4) 4 (4, 4) 4 (4, 4)
BMI (kg/m2) 24.4 (22.4, 29.1) 24.2 (22.0, 26.5) 25.2 (22.6, 29.2)
FEV1/FVC 0.84 (0.78, 0,86) 0.80 (0.77, 0,85) 0.84 (0.78, 0,87)
FVC (L) 1.83 (1.39, 2.44) 1.83 (1.44, 2.45) 1.82 (1.22, 2.44)
FVC (% predicted) 61.8 (49.8, 75.0) 63.0 (49.0, 78.2) 60.5 (50.0, 68.0)
DLCO (mL/min/mm Hg) 2.16 (1.71, 2.77) 2.50 (1.92, 3.36) 1.88 (1.64, 2.20)
DLCO (% predicted) 26.0 (21.9, 36.7) 36.5 (22.3, 40.4) 25.0 (20.8, 29.8)
Smoking status: never/former/current (%) 13 (59)/9 (41)/0 (0) 7 (64)/4 (36)/0 (0) 6 (55)/5 (45)/0 (0)
Smoking pack-year history 0 (0, 8) 0 (0, 5) 0 (0, 13)
Age-adjusted Charlson Comorbidity Index 2 (0, 5) 4 (0, 5) 0 (0, 6)
COPD, n (%) 3 (14) 1 (10) 2 (18)
Pulmonary hypertension, n (%) 2 (9) 0 (0) 2 (18)
Ischaemic heart disease, n (%) 8 (36) 5 (46) 3 (27)
Obstructive sleep apnoea, n (%) 0 (0) 0 (0) 0 (0)
Self-reported hospitalisations in previous year, n (%) 0 (0, 0) 0 (0, 0) 0 (0, 0)
Self-reported chest infections in previous year, n (%) 1 (1, 2) 1 (1, 2) 1 (1, 1)
Oxygen, n (%)
 Long term 4 (18) 1 (10) 3 (27)
 Ambulatory 9 (41) 4 (36) 5 (46)
Walking aid, n (%) 5 (23) 2 (18) 3 (27)
Prescribed pirfenidone, n (%) 6 (27) 4 (36) 2 (18)
Prescribed nintedanib, n (%) 7 (32) 4 (36) 3 (27)
Prescribed corticosteroid, n (%) 4 (18) 3 (27) 1 (9)
6MWT (m) 289 (149, 360) 326 (150, 361) 240 (130, 325)
SPPB score 9 (6, 11) 10 (6, 11) 7 (4, 11)
Four-metre gait speed (m/s) 0.71 (0.50, 0.94) 0.82 (0.38, 0.97) 0.66 (0.51, 0.84)
QMVC (kg) 22.4 (15.6, 28.7) 22.5 (15.1, 28.3) 22.4 (15.7, 31.3)
QMVC (% predicted) 62.4 (52.0, 69.1) 64.3 (44.0, 68.1) 61.6 (52.8, 72.2)
Rectus femoris cross-sectional area (mm2) 459 (371, 534) 451 (321, 579) 479 (375, 581)
KBILD—psychological 54.4 (53.2, 69.1) 58.8 (41.2, 71.6) 53.5 (43.8, 65.5)
KBILD—breathlessness and activities 35.6 (21.6, 45.9) 37.8 (27.0, 50.2) 35.6 (17.7, 41.9)
KBILD—chest symptoms 68.6 (44.0, 85.2) 63.7 (44.0, 85.2) 73.4 (54.3, 85.2)
KBILD—total score 53.5 (46.4, 59.4) 56.1 (43.9, 66.4) 53.5 (47.2, 56.1)
LCADL—self-care 6.0 (4.0, 8.0) 7.0 (4.0, 8.0) 6.0 (4.0, 7.0)
LCADL—domestic 10.5 (4.8, 18.5) 5.0 (1.0, 17.0) 14.0 (10.0, 22.0)
LCADL—physical 4.0 (3.0, 6.0) 4.0 (3.0, 5.0) 4.0 (3.0, 6.0)
LCADL—leisure 4.0 (3.0, 6.0) 4.0 (3.0, 6.0) 5.0 (4.0, 6.0)
LCADL—total score 26.0 (17.5, 37.3) 20.0 (14.0, 28.0) 33.0 (22.0, 29.0)
Daily step count 1511 (776, 3456) 1820 (1148, 3232) 988 (657, 4115)
Daily minutes spent in moderate-intensity PA 34 (20, 84) 47 (25, 100) 22 (5, 74)
Daily minutes spent in light-intensity PA 194 (147, 221) 217 (126, 248) 187 (153, 199)
Daily minutes spent sedentary 1144 (1098, 1206) 1123 (1095, 1151) 1194 (1137, 1237)

Data reported as number (percentage) or median (25th centile, 75th centile).

KBILD domains and total score: range 0–100; higher scores indicate better health-related quality of life.

LCADL range: self-care: 0–20; domestic: 0–30; physical: 0–10; leisure: 0–15; total: 0–75; higher scores indicate greater impact on activities of daily living (ADL) performance.

BMI, body mass index; COPD, chronic obstructive pulmonary disease; DLCO, diffusing capacity of the lung for carbon monoxide; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; KBILD, King’s Brief Interstitial Lung Disease questionnaire; LCADL, London Chest Activities of Daily Living questionnaire; MRC, Medical Research Council; 6MWT, 6 min walk test; PA, physical activity; QMVC, quadriceps maximum voluntary contraction; SPPB, Short Physical Performance Battery.